The Basel giant signs a partnership with Ratio Therapeutics with a view to developing a radiotherapeutic candidate for the treatment of cancer.
Novartis has entered into an exclusive global licensing and collaboration agreement with Ratio Therapeutics, a pharmaceutical company developing radiopharmaceuticals for the treatment and monitoring of cancer. The American laboratory will receive an undisclosed initial sum and could receive milestone payments of up to $745 million.
This partnership “leverages Ratio’s expertise in the discovery and development of radioligand therapies as well as its technology platforms for the development of an SSTR2 (somatostatin receptor 2) radiotherapeutic candidate for the treatment of cancer », Underlines the Basel pharmaceutical giant in a press release published Monday.
Novartis will assume responsibility for all remaining development, manufacturing and commercialization activities.
Under the terms of the agreement, Boston-based Ratio will also be eligible to receive installment royalty payments from Novartis.
Business
